S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:MRSN

Mersana Therapeutics (MRSN) Stock Price, News & Analysis

$4.48
-0.01 (-0.22%)
(As of 03/28/2024 ET)
Today's Range
$4.47
$4.71
50-Day Range
$2.71
$5.94
52-Week Range
$0.80
$9.62
Volume
1.40 million shs
Average Volume
3.01 million shs
Market Capitalization
$543.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.29

Mersana Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
40.3% Upside
$6.29 Price Target
Short Interest
Bearish
7.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.69
Upright™ Environmental Score
News Sentiment
0.64mentions of Mersana Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$127,663 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.60) to ($0.67) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.49 out of 5 stars

Medical Sector

105th out of 938 stocks

Pharmaceutical Preparations Industry

40th out of 432 stocks

MRSN stock logo

About Mersana Therapeutics Stock (NASDAQ:MRSN)

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

MRSN Stock Price History

MRSN Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
The Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 Experts
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Expert Outlook: Mersana Therapeutics Through The Eyes Of 5 Analysts
Q4 2023 Mersana Therapeutics Inc Earnings Call
Here's what Wall Street expects from Mersana Therapeutics's earnings
See More Headlines
Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRSN
Fax
N/A
Employees
123
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.29
High Stock Price Target
$9.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+40.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-171,670,000.00
Net Margins
-465.80%
Pretax Margin
-465.80%

Debt

Sales & Book Value

Annual Sales
$36.85 million
Book Value
$0.31 per share

Miscellaneous

Free Float
106,140,000
Market Cap
$543.42 million
Optionable
Optionable
Beta
1.53
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Martin H. Huber M.D. (Age 63)
    President, CEO & Director
    Comp: $44k
  • Mr. Brian C. DeSchuytner (Age 45)
    Senior VP, CFO & COO
    Comp: $626.32k
  • Dr. Timothy B. Lowinger Ph.D. (Age 60)
    Senior VP, Chief Science & Technology Officer
    Comp: $666.3k
  • Ms. Alejandra Veronica Carvajal J.D. (Age 50)
    SVP, Secretary & Chief Legal Officer
    Comp: $606.51k
  • Mr. Mikhail Papisov Ph.D.
    Co-Founder
  • Mr. Ashish MandeliaMr. Ashish Mandelia (Age 49)
    VP, Controller & Chief Accounting Officer
  • Mr. Jason Fredette
    Senior Vice President of Investor Relations & Corporate Communications
  • Mr. Chuck Miller
    Senior Vice President of Regulatory Affairs
  • Mr. Marc Damelin
    Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.
  • Dr. Tushar Misra Ph.D. (Age 64)
    SVP & Chief Manufacturing Officer
    Comp: $485.89k

MRSN Stock Analysis - Frequently Asked Questions

Should I buy or sell Mersana Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MRSN shares.
View MRSN analyst ratings
or view top-rated stocks.

What is Mersana Therapeutics' stock price target for 2024?

7 brokerages have issued 1 year price targets for Mersana Therapeutics' shares. Their MRSN share price targets range from $5.00 to $9.00. On average, they predict the company's share price to reach $6.29 in the next twelve months. This suggests a possible upside of 40.3% from the stock's current price.
View analysts price targets for MRSN
or view top-rated stocks among Wall Street analysts.

How have MRSN shares performed in 2024?

Mersana Therapeutics' stock was trading at $2.32 at the start of the year. Since then, MRSN shares have increased by 93.1% and is now trading at $4.48.
View the best growth stocks for 2024 here
.

Are investors shorting Mersana Therapeutics?

Mersana Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 8,730,000 shares, an increase of 22.3% from the February 29th total of 7,140,000 shares. Based on an average daily volume of 2,290,000 shares, the short-interest ratio is currently 3.8 days.
View Mersana Therapeutics' Short Interest
.

When is Mersana Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MRSN earnings forecast
.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) issued its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). The company earned $10.70 million during the quarter, compared to analysts' expectations of $22.59 million. Mersana Therapeutics had a negative net margin of 465.80% and a negative trailing twelve-month return on equity of 282.36%. The company's revenue was down 27.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.44) EPS.

What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO?

3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Mersana Therapeutics own?
When did Mersana Therapeutics IPO?

Mersana Therapeutics (MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Balyasny Asset Management L.P. (8.03%), Vanguard Group Inc. (5.17%), Vanguard Group Inc. (5.14%), Nextech Invest Ltd. (4.95%), Affinity Asset Advisors LLC (0.83%) and Northern Trust Corp (0.77%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Brian Deschuytner, Lawrence M Alleva, Mohan Bala, Timothy B Lowinger and Tushar Misra.
View institutional ownership trends
.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRSN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners